Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOS NASDAQ:LQDA NYSE:STVN NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$153.33-1.4%$134.80$73.16▼$161.53$9.01B0.75868,300 shs476,811 shsLQDALiquidia$80.89+4.9%$69.45$15.12▼$82.96$7.19B0.551.81 million shs1.16 million shsSTVNStevanato Group€19.11-0.2%€18.26€12.89▼€28.00€5.79B0.78552,974 shs261,996 shsWRBYWarby Parker$24.580.0%$26.63$14.96▼$31.00$2.63B1.913.17 million shs2.23 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos-0.91%+1.82%+18.85%+27.50%+59.10%LQDALiquidia-3.58%+8.24%+8.46%+112.63%+430.12%STVNStevanato Group+0.13%-2.71%+9.13%+25.52%-22.86%WRBYWarby Parker-6.55%-9.97%-4.69%-1.31%+3.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$153.33-1.4%$134.80$73.16▼$161.53$9.01B0.75868,300 shs476,811 shsLQDALiquidia$80.89+4.9%$69.45$15.12▼$82.96$7.19B0.551.81 million shs1.16 million shsSTVNStevanato Group€19.11-0.2%€18.26€12.89▼€28.00€5.79B0.78552,974 shs261,996 shsWRBYWarby Parker$24.580.0%$26.63$14.96▼$31.00$2.63B1.913.17 million shs2.23 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos-0.91%+1.82%+18.85%+27.50%+59.10%LQDALiquidia-3.58%+8.24%+8.46%+112.63%+430.12%STVNStevanato Group+0.13%-2.71%+9.13%+25.52%-22.86%WRBYWarby Parker-6.55%-9.97%-4.69%-1.31%+3.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.80Moderate Buy$154.850.99% UpsideLQDALiquidia 2.82Moderate Buy$68.88-14.85% DownsideSTVNStevanato Group 3.00BuyN/AN/AWRBYWarby Parker 2.67Moderate Buy$29.8221.32% UpsideCurrent Analyst Ratings BreakdownLatest WRBY, GKOS, LQDA, and STVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026GKOSGlaukos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026LQDALiquidia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026GKOSGlaukos Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$170.00 ➝ $175.007/16/2026STVNStevanato Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)7/16/2026GKOSGlaukos Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $180.007/13/2026GKOSGlaukos BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$164.007/8/2026GKOSGlaukos CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$162.00 ➝ $175.007/6/2026GKOSGlaukos HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$168.007/6/2026GKOSGlaukos HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$168.007/2/2026STVNStevanato Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)7/1/2026GKOSGlaukos Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$165.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$507.44M17.75N/AN/A$11.42 per share13.43LQDALiquidia$158.32M45.44N/AN/A$0.51 per share158.61STVNStevanato Group€1.34B4.31€0.88 per share21.73€5.55 per share3.44WRBYWarby Parker$871.91M3.02$0.59 per share41.98$3.48 per share7.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$187.69M-$3.28N/A326.24N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)LQDALiquidia-$68.92M$0.14577.8316.44N/A7.74%46.82%7.06%8/11/2026 (Estimated)STVNStevanato Group€158.21M€0.5932.3823.881.7711.76%10.27%6.08%N/AWRBYWarby Parker$1.64M$0.021,229.5161.455.280.15%2.30%1.18%8/6/2026 (Estimated)Latest WRBY, GKOS, LQDA, and STVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026LQDALiquidia$0.7580N/AN/AN/A$168.48 millionN/A8/6/2026Q2 2026WRBYWarby Parker$0.12N/AN/AN/A$237.98 millionN/A7/29/2026Q2 2026GKOSGlaukos-$0.2229N/AN/AN/A$150.99 millionN/A5/11/2026Q1 2026LQDALiquidia$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million5/8/2026Q1 2026STVNStevanato Group€0.12€0.11-€0.01€0.10N/A€273.57 million5/7/2026Q1 2026WRBYWarby Parker$0.11$0.03-$0.08$0.03$239.44 million$242.45 million4/29/2026Q1 2026GKOSGlaukos-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.105.434.73LQDALiquidia1.182.222.03STVNStevanato Group0.211.631.11WRBYWarby ParkerN/A2.332.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%LQDALiquidia64.54%STVNStevanato GroupN/AWRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos5.90%LQDALiquidia25.60%STVNStevanato GroupN/AWRBYWarby Parker16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos1,09458.73 million55.27 millionOptionableLQDALiquidia5088.93 million66.16 millionOptionableSTVNStevanato Group6,010302.84 millionN/AOptionableWRBYWarby Parker4,036107.09 million89.10 millionOptionableWRBY, GKOS, LQDA, and STVN HeadlinesRecent News About These CompaniesWarby Parker (NYSE:WRBY) Stock Price Down 6.1% - Here's WhyJuly 20 at 1:39 PM | marketbeat.comWarby Parker (WRBY) Stock Still Looks Pricey Following Its 85% RiseJuly 18 at 8:08 AM | finance.yahoo.comWarby Parker (WRBY) Faces A 12% Fair Value Gap Following Q2 Earnings Date SetJuly 18 at 8:08 AM | finance.yahoo.comWarby Parker to Announce Second Quarter 2026 Financial Results on August 6, 2026July 16, 2026 | finance.yahoo.comWarby Parker Inc. (NYSE:WRBY) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 16, 2026 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 16, 2026 | marketbeat.comNeil Harris Blumenthal Sells 9,200 Shares of Warby Parker (NYSE:WRBY) StockJuly 9, 2026 | insidertrades.comWarby Parker (NYSE:WRBY) CEO Neil Harris Blumenthal Sells 9,200 SharesJuly 8, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) Trading Down 6.3% - What's Next?July 8, 2026 | marketbeat.comSimplify Asset Management Inc. Sells 109,512 Shares of Warby Parker Inc. $WRBYJuly 4, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) CEO Sells 217,667 SharesJuly 3, 2026 | insidertrades.comInsider Selling: Warby Parker (NYSE:WRBY) CEO Sells 217,667 SharesJuly 2, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) CEO Sells $1,090,452.00 in StockJuly 2, 2026 | insidertrades.comNeil Harris Blumenthal Sells 36,300 Shares of Warby Parker (NYSE:WRBY) StockJuly 1, 2026 | marketbeat.comSG Americas Securities LLC Invests $2.71 Million in Warby Parker Inc. $WRBYJuly 1, 2026 | marketbeat.comWarby Parker disrupts eyewear industry with full-service eyewear retailer — BofAJune 29, 2026 | seekingalpha.comWarby Parker Has 'Plenty More Than Meets The Eye', Analyst SaysJune 29, 2026 | benzinga.comWarby Parker (NYSE:WRBY) Coverage Initiated by Analysts at Bank of AmericaJune 29, 2026 | marketbeat.comMaridea Wealth Management LLC Raises Holdings in Warby Parker Inc. $WRBYJune 27, 2026 | marketbeat.comWhat Does the Sale of Warby Parker Shares Worth $1.9 Million by the Co-CEO Mean for Investors?June 25, 2026 | fool.comVaughan Nelson Investment Management L.P. Purchases 722,627 Shares of Warby Parker Inc. $WRBYJune 22, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWRBY, GKOS, LQDA, and STVN Company DescriptionsGlaukos NYSE:GKOS$153.33 -2.13 (-1.37%) Closing price 03:59 PM EasternExtended Trading$153.15 -0.18 (-0.12%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Liquidia NASDAQ:LQDA$80.89 +3.81 (+4.94%) Closing price 04:00 PM EasternExtended Trading$80.84 -0.05 (-0.06%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Stevanato Group NYSE:STVN€19.10 -0.05 (-0.23%) Closing price 03:59 PM EasternExtended Trading€19.10 -0.01 (-0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.Warby Parker NYSE:WRBY$24.58 -0.01 (-0.05%) Closing price 03:59 PM EasternExtended Trading$24.60 +0.02 (+0.09%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
